| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
President Joe Biden's shaky debate performance this week is stirring doubts among Democrats about his viability for reelect...
Aurora Cannabis (NASDAQ: ACB), a key player in the global medical marijuana market, stands at a strategic crossroads. Pablo Zua...
Zuanic & Associates analyst Pablo Zuanic initiates coverage on Aurora Cannabis (NASDAQ:ACB) with a Neutral rating.
The financial landscapes of Canadian and U.S. cannabis operators showcase distinct paths in the quest for profitability, driven...
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced on Thursday its financial and operational results for the fourth quarte...
A short squeeze forces investors betting on a stock's decline (short sellers) to buy back shares at a higher price to avoid...
Explore the rapid growth of the medical cannabis packaging market, projected to reach $117.2 billion by 2032. Read now!
